CPX-351 in acute myeloid leukemia: can a new formulation maximize the efficacy of old compounds?

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7–30.
   PubMed Web of Science ®Google Scholar
• NCCN. National Comprehensive Cancer Network. Clinical practice guidelines in oncology. Acute myeloid leukemia. Version 1 2016. Available from: https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf2016.
   Google Scholar
• Howlader N, Noone AM, Krapcho M, et al., editors. SEER Cancer Statistics Review, 1975–2013, National Cancer Institute. Bethesda (MD). Based on November 2015 SEER data submission, posted to the SEER web site, April 2016. Available from: http://seer.cancer.gov/csr/1975_2013/
   Google Scholar
• Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–447.
   PubMed Web of Science ®Google Scholar
• Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115:453–474.
   PubMed Web of Science ®Google Scholar
• Dohner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373:1136–1152.
   PubMed Web of Science ®Google Scholar
• Middeke JM, Beelen D, Stadler M, et al. Outcome of high-risk acute myeloid leukemia after allogeneic hematopoietic cell transplantation: negative impact of abnl(17p) and −5/5q. Blood. 2012;120:2521–2528.
   PubMed Web of Science ®Google Scholar
• Frohling S, Schlenk RF, Kayser S, et al. Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. Blood. 2006;108:3280–3288.
   PubMed Web of Science ®Google Scholar
• Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood. 2006;107:3481–3485.
   PubMed Web of Science ®Google Scholar
• Grimwade D, Walker H, Harrison G, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood. 2001;98:1312–1320.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, O’Brien S, Cortes J, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer. 2006;106:1090–1098.
   PubMed Web of Science ®Google Scholar
• Farag SS, Archer KJ, Mrόzek K, et al. Cancer, Leukemia Group B. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood. 2006;108:63–73.
   PubMed Web of Science ®Google Scholar
• Juliusson G, Antunovic P, Derolf A, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood. 2009;113:4179–4187.
   PubMed Web of Science ®Google Scholar
• Diaz-Beya M, Rozman M, Pratcorona M, et al. The prognostic value of multilineage dysplasia in de novo acute myeloid leukemia patients with intermediate-risk cytogenetics is dependent on NPM1 mutational status. Blood. 2010;116:6147–6148.
   PubMed Web of Science ®Google Scholar
• Buchner T, Hiddemann W, Wormann B, et al. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. Blood. 1999;93:4116–4124.
   PubMed Web of Science ®Google Scholar
• Bishop JF, Matthews JP, Young GA, et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood. 1996;87:1710–1717.
   PubMed Web of Science ®Google Scholar
• Weick JK, Kopecky KJ, Appelbaum FR, et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood. 1996;88:2841–2851.
   PubMed Web of Science ®Google Scholar
• Goldstone AH, Burnett AK, Wheatley K, et al. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood. 2001;98:1302–1311.
   PubMed Web of Science ®Google Scholar
• Lowenberg B, Ossenkoppele GJ, van Putten W, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med. 2009;361:1235–1248.
   PubMed Web of Science ®Google Scholar
• Bishop JF, Lowenthal RM, Joshua D, et al. Etoposide in acute nonlymphocytic leukemia. Australian Leukemia Study Group. Blood. 1990;75:27–32.
   PubMed Web of Science ®Google Scholar
• Estey EH, Thall PF, Pierce S, et al. Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin ± all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Blood. 1999;93:2478–2484.
   PubMed Web of Science ®Google Scholar
• Estey EH, Thall PF, Cortes JE, et al. Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. Blood. 2001;98:3575–3583.
   PubMed Web of Science ®Google Scholar
• Wolff SN, Herzig RH, Fay JW, et al. High-dose cytarabine and daunorubicin as consolidation therapy for acute myeloid leukemia in first remission: long-term follow-up and results. J Clin Oncol. 1989;7:1260–1267.
   PubMed Web of Science ®Google Scholar
• Minakata D, Fujiwara S, Ito S, et al. A low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus a daunorubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia: a propensity score analysis. Leuk Res. 2016;42:82–87.
   PubMed Web of Science ®Google Scholar
• Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood. 1997;89:3323–3329.
   PubMed Web of Science ®Google Scholar
• DeLima M, Ghaddar H, Pierce S, et al. Treatment of newly-diagnosed acute myelogenous leukaemia in patients aged 80 years and above. Br J Haematol. 1996;93:89–95.
   PubMed Web of Science ®Google Scholar
• Estey EH. How I treat older patients with AML. Blood. 2000;96:1670–1673.
   PubMed Web of Science ®Google Scholar
• Stone RM, Mandrekar S, Sanford BL. The multi-kinase inhibitor midostaurin (M) prolongs survival compared with placebo (P) in combination with daunorubicin (D)/cytarabine (C) Induction (ind), high-dose C consolidation (consol), and as maintenance (maint) therapy in newly diagnosed acute myeloid leukemia (AML) patients (pts) age 18–60 with FLT3 mutations (muts): an international prospective randomized (rand) P-controlled double-blind trial (CALGB 10603/RATIFY [Alliance]). Blood. 2015;126:6.
   Web of Science ®Google Scholar
• Goldie JH, Coldman AJ. Application of theoretical models to chemotherapy protocol design. Cancer Treat Rep. 1986;70:127–131.
   PubMedGoogle Scholar
• Frei EEJ. Principles of dose, schedule, and combination therapy. In: Kufe DWBR, Hait WN, Hong WK, et al., editors. Holland-Frei cancer medicine. 7th ed. Hamilton (ON): BC decker; 2006. p. 590–599.
   Google Scholar
• Mayer LD, Harasym TO, Tardi PG, et al. Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol Cancer Ther. 2006;5:1854–1863.
   PubMed Web of Science ®Google Scholar
• Swaffar DS, Ang CY, Desai PB, et al. Combination therapy with 5-fluorouracil and L-canavanine: in vitro and in vivo studies. Anticancer Drugs. 1995;6:586–593.
   PubMed Web of Science ®Google Scholar
• Pavillard V, Kherfellah D, Richard S, et al. Effects of the combination of camptothecin and doxorubicin or etoposide on rat glioma cells and camptothecin-resistant variants. Br J Cancer. 2001;85:1077–1083.
   PubMed Web of Science ®Google Scholar
• Mayer LD, Janoff AS. Optimizing combination chemotherapy by controlling drug ratios. Mol Interv. 2007;7:216–223.
   PubMed Web of Science ®Google Scholar
• Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science. 2004;303:1818–1822.
   PubMed Web of Science ®Google Scholar
• Torchilin VP. Targeted pharmaceutical nanocarriers for cancer therapy and imaging. Aaps J. 2007;9:E128–47.
   PubMed Web of Science ®Google Scholar
• Sauvage F, Barratt G, Herfindal L, et al. The use of nanocarriers in acute myeloid leukaemia therapy: challenges and current status. Curr Pharm Biotechnol. 2016;17:30–41.
   PubMed Web of Science ®Google Scholar
• Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul. 2001;41:189–207.
   PubMedGoogle Scholar
• Tardi P, Johnstone S, Harasym N, et al. In vivo maintenance of synergistic cytarabine: daunorubicinratios greatly enhances therapeutic efficacy. Leuk Res. 2009;33:129–139.
   PubMed Web of Science ®Google Scholar
• Dicko A, Kwak S, Frazier AA, et al. Biophysical characterization of a liposomal formulation of cytarabine and daunorubicin. Int J Pharm. 2010;391:248–259.
   PubMed Web of Science ®Google Scholar
• Lim WS, Tardi PG, Dos Santos N, et al. Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine: daunorubicin formulation, in bone marrow xenografts. Leuk Res. 2010;34:1214–1223.
   PubMed Web of Science ®Google Scholar
• Chikayama S, Kimura S, Kobayashi Y, et al. Effects of daunorubicin on cell growth, cell cycle and induction of apoptosis in HL-60 cells. Haematologia (Budap). 1998;29:115–121.
   PubMedGoogle Scholar
• Skipper HE, Schabel FM Jr., Wilcox WS. Experimental evaluation of potential anticancer agents. XXI. Scheduling of arabinosylcytosine to take advantage of its S-phase specificity against leukemia cells. Cancer Chemother Rep. 1967;51:125–165.
   PubMedGoogle Scholar
• Belov L, de la Vega O, dos Remedios CG, et al. Immunophenotyping of leukemias using a cluster of differentiation antibody microarray. Cancer Res. 2001;61:4483–4489.
   PubMed Web of Science ®Google Scholar
• Xu Y, McKenna RW, Wilson KS, et al. Immunophenotypic identification of acute myeloid leukemia with monocytic differentiation. Leukemia. 2006;20:1321–1324.
   PubMed Web of Science ®Google Scholar
• Casasnovas RO, Slimane FK, Garand R, et al. Immunological classification of acute myeloblastic leukemias: relevance to patient outcome. Leukemia. 2003;17:515–527.
   PubMed Web of Science ®Google Scholar
• Banker DE, Mayer SJ, Li HY, et al. Cholesterol synthesis and import contribute to protective cholesterol increments in acute myeloid leukemia cells. Blood. 2004;104:1816–1824.
   PubMed Web of Science ®Google Scholar
• Kim HP, Gerhard B, Harasym TO, et al. Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells. Exp Hematol. 2011;39:741–750.
   PubMed Web of Science ®Google Scholar
• Robert J, Rigal-Huguet F, Hurteloup P. Comparative pharmacokinetic study of idarubicin and daunorubicin in leukemia patients. Hematol Oncol. 1992;10:111–116.
   PubMed Web of Science ®Google Scholar
• Fleming RA, Capizzi RL, Rosner GL, et al. Clinical pharmacology of cytarabine in patients with acute myeloid leukemia: a cancer and leukemia group B study. Cancer Chemother Pharmacol. 1995;36:425–430.
   PubMed Web of Science ®Google Scholar
• Lim WS, Tardi PG, Xie X, et al. Schedule- and dose-dependency of CPX-351, a synergistic fixed ratio cytarabine: daunorubicinformulation, in consolidation treatment against human leukemia xenografts. Leuk Lymphoma. 2010;51:1536–1542.
   PubMed Web of Science ®Google Scholar
• Carol H, Fan MM, Harasym TO, et al. Efficacy of CPX-351, (cytarabine: daunorubicin)liposome injection, against acute lymphoblastic leukemia (ALL) xenograft models of the Pediatric Preclinical Testing Program. Pediatr Blood Cancer. 2015;62:65–71.
   PubMed Web of Science ®Google Scholar
• Feldman EJ, Lancet JE, Kolitz JE, et al. First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. J Clin Oncol. 2011;29:979–985.
   PubMed Web of Science ®Google Scholar
• Gergis U, Roboz G, Shore T, et al. A phase I study of CPX-351 in combination with busulfan and fludarabine conditioning and allogeneic stem cell transplantation in adult patients with refractory acute leukemia. Biol Blood Marrow Transplant. 2013;19:1040–1045.
   PubMed Web of Science ®Google Scholar
• Lancet JE, Cortes JE, Hogge DE, et al. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML. Blood. 2014;123:3239–3246.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Goldberg SL, Feldman EJ, et al. Phase II, multicenter, randomized trial of CPX-351 (cytarabine: daunorubicin)liposome injection versus intensive salvage therapy in adults with first relapse AML. Cancer. 2015;121:234–242.
   PubMed Web of Science ®Google Scholar
• Lancet JE, Uy GL, Cortes JE, et al. Final results of a phase III randomized trial of CPX-351 versus 7+3 in older patients with newly diagnosed high risk (secondary) AML. American Society of Clinical Onclogy Meeting; 2016 Jun 3–7; Chicago, IL.
   Google Scholar
• Medeiros BC, Lancet JE, Cortes JE, et al. Analysis of efficacy by age for patients aged 60–75 with untreated secondary acute myeloid leukemia (AML) treated with CPX-351 liposome injection versus conventional cytarabine and daunorubicin in a Phase III trial. 58th Annual Meeting & Exposition; 2016 Dec 3–6; San Diego, CA.
   Google Scholar
• Lancet JE, Hoering A, Uy GL, et al. Survival following allogeneic hematopoietic cell transplantation in older high-risk acute myeloid leukemia patients initially treated with CPX-351 liposome injection versus standard cytarabine and daunorubicin: subgroup analysis of a large Phase III trial. 58th Annual Meeting & Exposition; 2016 Dec 3–6; San Diego, CA.
   Google Scholar
• Sonneveld P, List AF. Chemotherapy resistance in acute myeloid leukaemia. Best Pract Res Clin Haematol. 2001;14:211–233.
   PubMed Web of Science ®Google Scholar
• Sadava D, Coleman A, Kane SE. Liposomal daunorubicin overcomes drug resistance in human breast, ovarian and lung carcinoma cells. J Liposome Res. 2002;12:301–309.
   PubMed Web of Science ®Google Scholar
• Mayer LD, Shabbits JA. The role for liposomal drug delivery in molecular and pharmacological strategies to overcome multidrug resistance. Cancer Metastasis Rev. 2001;20:87–93.
   PubMed Web of Science ®Google Scholar
• Thierry AR, Dritschilo A, Rahman A. Effect of liposomes on P-glycoprotein function in multidrug resistant cells. Biochem Biophys Res Commun. 1992;187:1098–1105.
   PubMed Web of Science ®Google Scholar
• Warren L, Jardillier JC, Malarska A, et al. Increased accumulation of drugs in multidrug-resistant cells induced by liposomes. Cancer Res. 1992;52:3241–3245.
   PubMed Web of Science ®Google Scholar
• Dong X, Mumper RJ. Nanomedicinal strategies to treat multidrug-resistant tumors: current progress. Nanomedicine (Lond). 2010;5:597–615.
   PubMed Web of Science ®Google Scholar
• Gordon MJ, Tardi P, Loriaux MM, et al. CPX-351 exhibits potent and direct ex vivo cytotoxicity against AML blasts with enhanced efficacy for cells harboring the FLT3-ITD mutation. Leuk Res. 2017;53:39–49.
   PubMed Web of Science ®Google Scholar
• Ramanathan RK, Korn R, Raghunand N, et al. Correlation between ferumoxytol uptake in tumor lesions by MRI and response to nanoliposomal irinotecan in patients with advanced solid tumors: a pilot study. Clin Cancer Res. 2017;23:3638–3648.
   PubMed Web of Science ®Google Scholar
• Shi J, Kantoff PW, Wooster R, et al. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer. 2017;17:20–37.
   PubMed Web of Science ®Google Scholar
• Zhao X, Li H, Lee RJ. Targeted drug delivery via folate receptors. Expert Opin Drug Deliv. 2008;5:309–319.
   PubMed Web of Science ®Google Scholar
• Lu Y, Wu J, Wu J, et al. Role of formulation composition in folate receptor-targeted liposomal doxorubicin delivery to acute myelogenous leukemia cells. Mol Pharm. 2007;4:707–712.
   PubMed Web of Science ®Google Scholar
• Ono M, Takimoto R, Osuga T, et al. Targeting Notch-1 positive acute leukemia cells by novel fucose-bound liposomes carrying daunorubicin. Oncotarget. 2016;7:38586–38597.
   PubMed Web of Science ®Google Scholar
• Bose P, Vachhani P, Cortes JE. Treatment of relapsed/refractory acute myeloid leukemia. Curr Treat Options Oncol. 2017;18:17.
   PubMed Web of Science ®Google Scholar